Bio-Path (NASDAQ:BPTH) Announces Quarterly Earnings Results

Bio-Path (NASDAQ:BPTH) released its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.02, MarketWatch Earnings reports. During the same quarter last year, the firm earned ($0.49) EPS.

Bio-Path Price Performance

NASDAQ:BPTH traded down $0.01 during mid-day trading on Friday, reaching $0.53. The company’s stock had a trading volume of 66,960 shares, compared to its average volume of 885,266. The stock has a market cap of $6.55 million, a P/E ratio of -0.27 and a beta of 1.11. The company’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.95. Bio-Path has a twelve month low of $0.32 and a twelve month high of $2.35.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in Bio-Path during the third quarter worth approximately $35,000. Virtu Financial LLC purchased a new position in Bio-Path in the 1st quarter worth approximately $38,000. Finally, Renaissance Technologies LLC acquired a new stake in Bio-Path during the 2nd quarter valued at $70,000. 5.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Bio-Path in a research note on Thursday. They issued a “sell” rating for the company.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.